{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:57:08Z","timestamp":1790884628848,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"ministero della salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from phase II-III randomized trials of advanced or recurrent EC reporting patient-reported outcomes (PROs) were reviewed. Eligible studies assessed health-related QoL using validated instruments. The review focused on trials that met their primary endpoint and reported QoL or PROs in peer-reviewed publications and\/or congress presentations. Data extraction and appraisal were conducted independently by the authors, and findings were synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the RUBY trial, dostarlimab plus chemotherapy prolonged time to deterioration and delayed permanent QoL decline in mismatch repair-deficient (dMMR)\/microsatellite instability-high (MSI-H) patients. NRG-018 explored QoL in the mismatch repair-proficient (pMMR) cohort, with later planned time points still pending full publication. AtTEnd trial reported no clinically meaningful deterioration in global QoL with atezolizumab plus chemotherapy. In DUO-E, QoL was maintained with durvalumab-based strategies, with clinically meaningful physical functioning gains in the dMMR subgroup. In KEYNOTE-775, global QoL was broadly comparable between lenvatinib plus pembrolizumab and chemotherapy, although differences emerged in selected symptom domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>QoL provides a direct, patient-centered assessment of disease burden and treatment impact, complementing efficacy endpoints. However, QoL analyses remain inconsistently reported, delayed, and difficult to compare. Strengthening the integration and standardized reporting of PROs is essential to better define treatment value in advanced EC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916261468178","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:03:27Z","timestamp":1790748207000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life in first-line trials for endometrial cancer: A systematic review"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7377-0888","authenticated-orcid":false,"given":"Valentina","family":"Tuninetti","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-8041","authenticated-orcid":false,"given":"Alberto","family":"Farolfi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast &amp; GYN Unit, IRCCS Istituto Romagnolo per lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d, Meldola (FC), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Buttic\u00e8","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-749X","authenticated-orcid":false,"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast &amp; GYN Unit, IRCCS Istituto Romagnolo per lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d, Meldola (FC), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-6261","authenticated-orcid":false,"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Breast &amp; GYN Unit, IRCCS Istituto Romagnolo per lo Studio Dei Tumori (IRST) \u201cDino Amadori\u201d, Meldola (FC), Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2342-2312","authenticated-orcid":false,"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, A.O.U. Citta ` della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111448"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102701"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"e_1_3_2_7_2","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E Trial","author":"Westin SN","year":"2023","unstructured":"Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E Trial. J Clin Oncol 2023; JCO2302132.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103538"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw153"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"e_1_3_2_14_2","article-title":"633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"24","author":"Boere I","year":"2024","unstructured":"Boere I, Pothuri B, Sukhina O, et al. 633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial. Int J Gynecol Cancer 2024; 24: A26-A28.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005484"},{"key":"e_1_3_2_16_2","article-title":"PO001\/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA\/REC)","volume":"34","author":"Cloven N","year":"2025","unstructured":"Cloven N, Roed H, Gilbert L, et al. PO001\/#1130 Impact of investigator-assessed response to dostarlimab on quality of life in the ruby trial of primary advanced or recurrent endometrial cancer (PA\/REC). Int J Gynecol Cancer 2025; 34: A14-A15.","journal-title":"Int J Gynecol Cancer"},{"key":"e_1_3_2_17_2","article-title":"Patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with chemotherapy plus dostarlimab or placebo in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial over 3 years of follow-up","volume":"35","author":"Sharma S","year":"2025","unstructured":"Sharma S, Lindahl G, Landrum LM, et al. Patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with chemotherapy plus dostarlimab or placebo in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial over 3 years of follow-up. Int J Gyne Cancer 2025; 35: 100243.","journal-title":"Int J Gyne Cancer"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00334-6"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101701"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.03.015"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr493"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.032"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.025"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-010713-141500"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9334"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.222"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2056"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70146-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy449"},{"key":"e_1_3_2_33_2","article-title":"Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study","volume":"2","author":"Marandino L","year":"2023","unstructured":"Marandino L, Trastu F, Ghisoni E, et al. Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study. BMJ Oncol 2023; 2: e000021.","journal-title":"BMJ Oncol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.11.007"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0111"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDra2400340"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004069"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916261468178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916261468178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916261468178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:16:24Z","timestamp":1790882184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916261468178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":38,"alternative-id":["10.1177\/03008916261468178"],"URL":"https:\/\/doi.org\/10.1177\/03008916261468178","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"03008916261468178"}}